CA2628558A1 - Modified annexin proteins and methods for their use in organ transplantation - Google Patents

Modified annexin proteins and methods for their use in organ transplantation Download PDF

Info

Publication number
CA2628558A1
CA2628558A1 CA002628558A CA2628558A CA2628558A1 CA 2628558 A1 CA2628558 A1 CA 2628558A1 CA 002628558 A CA002628558 A CA 002628558A CA 2628558 A CA2628558 A CA 2628558A CA 2628558 A1 CA2628558 A1 CA 2628558A1
Authority
CA
Canada
Prior art keywords
annexin
seq
protein
isolated
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002628558A
Other languages
English (en)
French (fr)
Inventor
Anthony Allison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alavita Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2628558A1 publication Critical patent/CA2628558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dentistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002628558A 2005-11-03 2006-10-25 Modified annexin proteins and methods for their use in organ transplantation Abandoned CA2628558A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/267,837 2005-11-03
US11/267,837 US7635676B2 (en) 2001-02-21 2005-11-03 Modified annexin proteins and methods for their use in organ transplantation
PCT/US2006/060227 WO2007073509A2 (en) 2005-11-03 2006-10-25 Modified annexin proteins and methods for their use in organ transplantation

Publications (1)

Publication Number Publication Date
CA2628558A1 true CA2628558A1 (en) 2007-06-28

Family

ID=38189136

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002628558A Abandoned CA2628558A1 (en) 2005-11-03 2006-10-25 Modified annexin proteins and methods for their use in organ transplantation

Country Status (6)

Country Link
US (3) US7635676B2 (https=)
EP (1) EP1957095A4 (https=)
JP (1) JP2009514553A (https=)
AU (1) AU2006327095A1 (https=)
CA (1) CA2628558A1 (https=)
WO (1) WO2007073509A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
JP4191189B2 (ja) * 2005-12-08 2008-12-03 康生 梅津 がん関連遺伝子活性化能を有するペプチド
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
CA2708956C (en) * 2007-12-18 2018-07-17 Athera Biotechnologies Ab Use of annexin a5 for the treatment of vascular disease
ES2530228T3 (es) * 2008-08-26 2015-02-27 Mosamedix B.V. Anexinas radiomarcadas
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
US20140037614A1 (en) * 2011-04-05 2014-02-06 Knut Pettersson Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
US9361735B1 (en) 2014-07-11 2016-06-07 State Farm Mutual Automobile Insurance Company Method and system of using spatial sensors on vehicle frame to determine crash information
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP4313020A4 (en) * 2021-03-26 2025-01-29 Emory University MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRUS INFECTIONS AND RELATED COMPOUNDS

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200A (en) * 1837-05-22 Geoege
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
KR930007434B1 (ko) * 1984-09-21 1993-08-10 베링거 잉겔하임 인터내셔날 게엠베하 혈액응고 억제 단백질 제조방법
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
JPH08840B2 (ja) * 1986-11-14 1996-01-10 興和株式会社 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
PT87083B (pt) 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE3737239A1 (de) 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
DE68923107T2 (de) * 1988-02-26 1996-01-18 Biogen Inc DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI.
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2055234T3 (es) * 1989-07-15 1994-08-16 Boehringer Ingelheim Int Agente con contenido de anticoagulante.
ES2045669T3 (es) * 1989-07-15 1994-01-16 Boehringer Ingelheim Int Procedimiento para la purificacion de anexinas.
DE3937607A1 (de) 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
DE3942081A1 (de) * 1989-12-20 1991-06-27 Behringwerke Ag Mittel zur verbesserung der wiederfindung von annexinen
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
JPH05507090A (ja) 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
CA2092315A1 (en) 1990-11-02 1992-05-03 John P. Burnier Platelet aggregation inhibitors
CA2096520C (en) * 1990-11-20 2000-12-19 Hiroshi Nakao Therapeutic agent for skin or corneal disease
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5229367A (en) * 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
EP0538459A4 (en) 1991-05-09 1993-06-16 The Board Of Regents Of The University Of Washington Phospholipid-targeted thrombolytic agents
JPH051096A (ja) 1991-06-26 1993-01-08 Kowa Co 抗血液凝固活性を持つオリゴペプチド
EP1138334A3 (en) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
CA2139735A1 (en) 1992-07-08 1994-01-20 Sing-Hiem Yap Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
JP3416912B2 (ja) 1992-10-08 2003-06-16 興和株式会社 抗血液凝固活性を持つオリゴペプチド
JPH0772149A (ja) 1993-06-30 1995-03-17 Nippon Shinyaku Co Ltd 肝癌又は肝硬変の診断薬及び診断法
JPH0772147A (ja) 1993-07-02 1995-03-17 Noboru Kaneko 抗アネキシンｖ抗体並びに該抗体の製法及び利用
US5849600A (en) * 1993-11-10 1998-12-15 The Mclean Hospital Corporation Diagnostic assays for Alzheimer's disease
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
JPH10504534A (ja) 1994-06-16 1998-05-06 ネオルクス コーポレイション 放射性標識アネキシン−ガラクトース結合体
ES2139957T3 (es) 1994-07-23 2000-02-16 Roche Diagnostics Gmbh Metodo para la determinacion del estado pretrombotico.
DE19541284C2 (de) 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
AU1520097A (en) 1995-12-27 1997-07-28 Genentech Inc. Ob protein derivatives having prolonged half-life
AU731924B2 (en) 1996-07-05 2001-04-05 Philip E. Branton Adenovirus E4 proteins for inducing cell death
JP2001508054A (ja) 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
CA2277757C (en) 1997-01-15 2008-09-16 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
AU8388098A (en) 1997-07-11 1999-02-08 Mount Sinai School Of Medicine Of The City University Of New York, The Assays for diagnosis of thrombophilic disease
DE19734648A1 (de) * 1997-08-11 1999-02-18 Dade Behring Marburg Gmbh Verwendung von Annexinen als Lupus Antikoagulans Kontrolle oder Standard in Gerinnungstesten
US6511829B1 (en) 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
WO1999048916A2 (en) 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US20040002056A1 (en) * 1998-05-12 2004-01-01 Lorens James B. Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US7067109B1 (en) * 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
WO2000010673A1 (en) 1998-08-24 2000-03-02 Nst Neurosurvival Technologies Ltd. Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
JP2002525289A (ja) 1998-09-01 2002-08-13 イノジェネティックス・ナムローゼ・フェンノートシャップ アネキシンに結合するベンゾジアゼピンおよびベンゾチアゼピン誘導体ならびにｈｓｂｓａｇペプチド、それらの組成物ならびに使用
SE9803218L (sv) 1998-09-23 1999-12-06 Peter Leksell Lagerhållare innefattande åtminstone två koaxialt efter varandra anordnade lager
US6387366B1 (en) 1998-12-31 2002-05-14 Alg Company Methods for reducing adverse side effects associated with cellular transplantation
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
US20020088015A1 (en) * 1999-06-04 2002-07-04 Yang Shi Wilms' tumor wt1 binding proteins
CZ2002341A3 (cs) * 1999-07-28 2002-09-11 Interface Biotech A/S Chrupavková membrána a její použití
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
WO2001023426A2 (en) 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
AU1465801A (en) 1999-11-03 2001-05-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
FR2809181B1 (fr) * 2000-05-16 2002-10-25 Biocytex Monoreactif pour le dosage des microparticules plaquettaires
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
WO2002020769A1 (en) 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
US7582443B2 (en) * 2000-11-28 2009-09-01 Philip Gerard Cavanaugh Method for the detection and measurement of Hapten-conjugated biological binding entities by western and dot-blot using anti-hapten antibodies
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
WO2002067767A2 (en) 2001-02-21 2002-09-06 Imetrx, Inc. Methods and systems which use annexin for bioprofiling body lumen
US6962903B2 (en) * 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
JP2004535375A (ja) 2001-04-03 2004-11-25 テセウス イメージング コーポレーション 生体内における細胞死の検出および随伴する症状の治療のためのアネキシンの使用方法
US20030003048A1 (en) 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
ATE458199T1 (de) 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
US20030027763A1 (en) * 2001-06-07 2003-02-06 Rigel Pharmaceuticals, Incorporated CD43: modulators of mast cell degranulation
CN1343777A (zh) 2001-06-26 2002-04-10 上海动物生物技术研究中心 葡激酶与Annexin V融合基因的构建及表达
WO2003021229A2 (en) * 2001-09-05 2003-03-13 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
CN1277581C (zh) 2001-09-14 2006-10-04 浙江中奇生物药业股份有限公司 一种用蚕生产抗血栓药物的方法
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
US20050176005A1 (en) 2002-01-16 2005-08-11 Spear Matthew A. Functional ligand display
US20030211548A1 (en) 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
US7713981B2 (en) 2002-02-28 2010-05-11 University Of Central Florida Method and compounds for inhibition of cell death
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20040022731A1 (en) 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1659180B (zh) 2002-06-06 2010-06-02 温子坚 新型的重组抗凝血蛋白
WO2004006963A1 (en) 2002-07-12 2004-01-22 Beth Israel Deaconess Medical Center Conjugated infrared fluorescent substances for detection of cell death
CN1181099C (zh) 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
DE10253526A1 (de) * 2002-11-16 2004-06-09 Johann Wolfgang Goethe-Universität Frankfurt am Main Endothelzellen als Diagnoseinstrument bei kardiovaskulären Erkrankungen
US20040203069A1 (en) 2003-04-10 2004-10-14 Chris Reutelingsperger Method for determining and/or isolating lipid-binding compounds
WO2004112717A2 (en) 2003-06-17 2004-12-29 Harrison Roger G Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
WO2004113561A2 (en) 2003-06-25 2004-12-29 Queen's University At Kingston Methods for diagnosing, monitoring, staging and treating heart failure
WO2005014801A1 (en) 2003-08-04 2005-02-17 University Court Of The University Of Edinburgh Improvements in cell culture productivity
WO2005018436A2 (en) 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
IL157786A (en) * 2003-09-07 2010-11-30 Ahava Dead Sea Lab Ltd Personalized cosmetics
WO2005023096A2 (en) 2003-09-09 2005-03-17 Point Biomedical Corporation Methods and compositions for ultrasound imaging of apoptosis
US20050084547A1 (en) * 2003-09-12 2005-04-21 Phytomyco Research Corporation Natural product based apoptosis inducers
WO2005028490A1 (en) 2003-09-19 2005-03-31 Theseus Imaging Corporation Halogenated deoxy-glucose labeled targeting molecules
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
EP1684579A1 (en) * 2003-10-22 2006-08-02 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
CA2485722A1 (en) * 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
WO2005042002A2 (en) * 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
CA2546649A1 (en) 2003-11-26 2005-06-16 Entelos, Inc. Treatment of rheumatoid arthritis with hypoxia-inducible factor 1.alpha. antagonists
WO2005058352A2 (en) 2003-12-17 2005-06-30 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
WO2005058351A2 (en) 2003-12-17 2005-06-30 Entelos, Inc. Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers
WO2005065418A2 (en) 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US20060134602A1 (en) 2004-01-13 2006-06-22 Littlefield Bruce A Methods of identifying cytotoxic effects in quiescent cells
CA2555866A1 (en) 2004-02-16 2005-08-25 Proteosys Ag Diagnostic markers for cancer
EP1734983A4 (en) * 2004-03-11 2009-11-18 Alavita Pharmaceuticals Inc MODIFIED ANNEXINE PROTEINS AND METHODS FOR PREVENTING THROMBOSIS
WO2005087275A2 (en) 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
WO2005103720A1 (en) 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
ES2356364T3 (es) 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.

Also Published As

Publication number Publication date
US7635678B2 (en) 2009-12-22
US20070054855A1 (en) 2007-03-08
US7635676B2 (en) 2009-12-22
WO2007073509A2 (en) 2007-06-28
EP1957095A4 (en) 2009-11-11
EP1957095A2 (en) 2008-08-20
AU2006327095A2 (en) 2008-10-09
AU2006327095A1 (en) 2007-06-28
WO2007073509A8 (en) 2008-10-02
US20070207150A1 (en) 2007-09-06
US20060105952A1 (en) 2006-05-18
WO2007073509A3 (en) 2007-11-29
JP2009514553A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
US20050222030A1 (en) Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) Modified annexin proteins and methods for their use in organ transplantation
EP2059806A2 (en) Modified annexin proteins and methods for their use in platelet storage and transfusion
US7635680B2 (en) Attenuation of reperfusion injury
US7407475B2 (en) Modified annexin proteins, and methods and compositions for using them
JP2012254992A (ja) 修飾アネキシンタンパク質および血栓症を防止するための方法
US20090291086A1 (en) Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
JP4873784B2 (ja) 膜結合能を有する可溶性ペプチド化合物の複合体を含有する器官移植用溶液
WO2004013303A2 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
US6982154B2 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20121025